Providence Laboratory Services offers Prosigna Breast Cancer Prognostic Gene Signature assay
July 31, 2014
Providence Regional Laboratory is excited to announce the launch of the Prosigna Breast Cancer Prognostic Gene Signature assay on August 4, 2014. The assay will be performed locally at the Providence Regional Lab. This next generation diagnostic test has robust clinical validation coupled with a unique decentralized delivery model that will reduce turn-around time for results.
The Prosigna Breast Cancer Prognostic Gene Signature array is:
- The only PAM50-based breast cancer genomic signature – translates tumor biology into individual risk
- The only genomic breast cancer assay that can be run in your pathology lab – enabling direct pathology to oncology/surgeon communication
- The only test that is FDA 510(k) cleared on FFPE tissue – rigorous clinical and analytical validation data
- Possible to run in as few as seven working days when starting from FFPE sample
Learn more about the Prosigna Breast Cancer Prognostic Gene Signaure assay, its indications, methodology, specimen requirements and reporting in our printable PDF or by visiting Prosigna.com.
Download Providence Laboratory Services' Clinical Update PDF
for the Prosigna Breast Cancer Prognostic Gene Signature assay.